Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Average Rating of “Moderate Buy” from Brokerages

Oncolytics Biotech Inc. (NASDAQ:ONCY) has earned an average recommendation of “Moderate Buy” from the five research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $8.50.

ONCY has been the subject of several recent research reports. HC Wainwright increased their price target on shares of Oncolytics Biotech from $5.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, November 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncolytics Biotech in a report on Monday, December 29th. Finally, Wall Street Zen lowered Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th.

Insider Buying and Selling

In related news, insider Andrew Aromando acquired 29,600 shares of the company’s stock in a transaction on Wednesday, February 11th. The stock was purchased at an average cost of $0.86 per share, for a total transaction of $25,456.00. Following the completion of the purchase, the insider directly owned 55,100 shares of the company’s stock, valued at $47,386. The trade was a 116.08% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Patricia S. Andrews acquired 35,400 shares of the business’s stock in a transaction on Thursday, February 12th. The shares were bought at an average cost of $0.86 per share, with a total value of $30,444.00. Following the completion of the acquisition, the director owned 78,128 shares of the company’s stock, valued at approximately $67,190.08. This trade represents a 82.85% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 389,232 shares of company stock worth $348,084 in the last quarter. Corporate insiders own 0.10% of the company’s stock.

Institutional Investors Weigh In On Oncolytics Biotech

Large investors have recently made changes to their positions in the company. Seeds Investor LLC increased its position in shares of Oncolytics Biotech by 17.8% during the 2nd quarter. Seeds Investor LLC now owns 223,767 shares of the company’s stock worth $173,000 after purchasing an additional 33,826 shares in the last quarter. Citadel Advisors LLC acquired a new position in Oncolytics Biotech in the third quarter valued at about $535,000. Scientech Research LLC bought a new stake in Oncolytics Biotech during the third quarter worth about $25,000. Ground Swell Capital LLC bought a new stake in Oncolytics Biotech during the fourth quarter worth about $30,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in shares of Oncolytics Biotech during the fourth quarter worth approximately $44,000. Institutional investors own 6.82% of the company’s stock.

Oncolytics Biotech Stock Performance

Shares of ONCY stock opened at $1.01 on Thursday. The firm has a fifty day moving average of $1.01 and a 200-day moving average of $1.08. The stock has a market cap of $107.21 million, a price-to-earnings ratio of -3.61 and a beta of 0.92. Oncolytics Biotech has a 52-week low of $0.33 and a 52-week high of $1.51.

About Oncolytics Biotech

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.